Harvard Bioscience (HBIO) Rejects Skystone Buyout Offer
HBIO Hot Sheet
EPS Growth %: +28.6%
Harvard Bioscience (Nasdaq: HBIO) today announced that its Board of Directors unanimously rejected an unsolicited buyout offer from Skystone Advisors LLC to acquire all outstanding shares of the Company's common stock for $5.00 per share.
Harvard Bioscience, Inc. develops, distributes, manufactures, and markets apparatus and scientific instruments used in life science research at pharmaceutical and biotechnology companies, universities, and government laboratories worldwide.
Harvard Bioscience, Inc. develops, distributes, manufactures, and markets apparatus and scientific instruments used in life science research at pharmaceutical and biotechnology companies, universities, and government laboratories worldwide.
You May Also Be Interested In
- BofA (BAC), Barclays (BCS) to Sell Remaining Archstone Interest in $1.58B Deal to Lehman Bros.
- BlackRock (BLK) Substantially Boosts Stake in Chesapeake (CHK) -CNBC's Kelly
- UPDATE: RR Donnelley (RRD) to Buy Edgar Online (EDGR) for $70.5M
Create E-mail Alert Related Categories
Corporate News, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
